UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical presentation and diagnosis of non-Hodgkin lymphoma

Authors
Arnold S Freedman, MD
Jonathan W Friedberg, MD
Jon C Aster, MD
Section Editor
Andrew Lister, MD, FRCP, FRCPath, FRCR
Deputy Editor
Alan G Rosmarin, MD

INTRODUCTION

Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant neoplasms variously derived from B cell progenitors, T cell progenitors, mature B cells, mature T cells, or (rarely) natural killer cells.

This topic will review the initial evaluation of a patient with suspected NHL. The classification, staging and prognosis of NHL, including specific details on the use of imaging modalities and the diagnosis of individual NHL variants, are discussed separately. (See "Evaluation and staging of non-Hodgkin lymphoma" and "Classification of the hematopoietic neoplasms".)

CLINICAL PRESENTATION

General — The clinical presentation of NHL varies tremendously depending upon the type of lymphoma and the areas of involvement. Some NHLs behave indolently with lymphadenopathy waxing and waning over years. Others are highly aggressive, resulting in death within weeks if left untreated. In typical cases:

Aggressive lymphomas commonly present acutely or subacutely with a rapidly growing mass, systemic B symptoms (ie, fever, night sweats, weight loss), and/or elevated levels of serum lactate dehydrogenase and uric acid. Examples of lymphomas with this aggressive or highly aggressive presentation include diffuse large B cell lymphoma, Burkitt lymphoma, adult T cell leukemia-lymphoma, and precursor B and T lymphoblastic leukemia/lymphoma.

Indolent lymphomas are often insidious, presenting only with slow growing lymphadenopathy, hepatomegaly, splenomegaly, or cytopenias. Examples of lymphomas that typically have indolent presentations include follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and splenic marginal zone lymphoma.

                                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Oct 28 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50:2699.
  2. Ghobrial IM, Wolf RC, Pereira DL, et al. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc 2004; 79:169.
  3. Ottinger H, Belka C, Kozole G, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995; 54:186.
  4. Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005; 92:1349.
  5. Caruso V, Di Castelnuovo A, Meschengieser S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 2010; 115:5322.
  6. Zhou X, Teegala S, Huen A, et al. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 2010; 123:935.
  7. Grigoropoulos NF, Shaw AS, Hampson FA, et al. Incidental pulmonary emboli in lymphoma patients are associated with aggressive disease and poor prognosis. J Thromb Haemost 2010; 8:2835.
  8. Viala K, Béhin A, Maisonobe T, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry 2008; 79:778.
  9. Graus F, Ariño H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014; 123:3230.
  10. Frumkin H. Agent Orange and cancer: an overview for clinicians. CA Cancer J Clin 2003; 53:245.
  11. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005; 162:1153.
  12. Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004; 110:380.
  13. Negri E, Little D, Boiocchi M, et al. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004; 111:1.
  14. Takkouche B, Etminan M, Montes-Martínez A. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 2005; 293:2516.
  15. Altieri A, Bermejo JL, Hemminki K. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 2005; 106:668.
  16. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121.
  17. Brennan P, Scélo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93:159.
  18. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98:51.
  19. Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006; 166:2101.
  20. Chiu BC, Dave BJ, Blair A, et al. Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood 2006; 108:1363.
  21. Rafnsson V. Risk of non-Hodgkin's lymphoma and exposure to hexachlorocyclohexane, a nested case-control study. Eur J Cancer 2006; 42:2781.
  22. Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007; 57:161.
  23. Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005; 97:1466.
  24. Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109:3479.
  25. Lu Y, Sullivan-Halley J, Cozen W, et al. Family history of haematopoietic malignancies and non-Hodgkin's lymphoma risk in the California Teachers Study. Br J Cancer 2009; 100:524.
  26. Goldin LR, Björkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91.
  27. Herro E, Dicaudo DJ, Davis MD, et al. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 2009; 61:271.
  28. Clarke CA, Morton LM, Lynch C, et al. Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer 2013; 109:280.
  29. Zhang Y, Sanjose SD, Bracci PM, et al. Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. Am J Epidemiol 2008; 167:1321.
  30. Eriksson M, Hardell L, Carlberg M, Akerman M. Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer 2008; 123:1657.
  31. Agopian J, Navarro JM, Gac AC, et al. Agricultural pesticide exposure and the molecular connection to lymphomagenesis. J Exp Med 2009; 206:1473.
  32. Thompson CA, Habermann TM, Wang AH, et al. Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study. Int J Cancer 2010; 126:992.
  33. Chang ET, Canchola AJ, Cockburn M, et al. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood 2011; 118:1591.
  34. Ollberding NJ, Maskarinec G, Conroy SM, et al. Prediagnostic circulating carotenoid levels and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort. Blood 2012; 119:5817.
  35. Cahoon EK, Pfeiffer RM, Wheeler DC, et al. Relationship between ambient ultraviolet radiation and non-Hodgkin lymphoma subtypes: a U.S. population-based study of racial and ethnic groups. Int J Cancer 2015; 136:E432.
  36. Ulcickas Yood M, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007; 46:107.
  37. Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007; 109:1360.
  38. Castillo JJ, Dalia S, Pascual SK. Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood 2010; 116:2897.
  39. Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111:4029.
  40. Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 2009; 124:1497.
  41. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009; 125:398.
  42. Fallah M, Liu X, Ji J, et al. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 2014; 25:2025.
  43. Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 2010; 15:1083.
  44. Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011; 47:2422.
  45. Krikorian JG, Portlock CS, Cooney P, Rosenberg SA. Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer 1980; 46:2093.
  46. Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin's lymphomas. Semin Oncol 1990; 17:43.
  47. Urquhart A, Berg R. Hodgkin's and non-Hodgkin's lymphoma of the head and neck. Laryngoscope 2001; 111:1565.
  48. Bhatia S, Paulino AC, Buatti JM, et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002; 54:818.
  49. Filly R, Bland N, Castellino RA. Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin's disease and non-Hodgkin's lymphoma. Radiology 1976; 120:277.
  50. Goffinet DR, Castellino RA, Kim H, et al. Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas. Cancer 1973; 32:672.
  51. Risdall R, Hoppe RT, Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer 1979; 44:529.
  52. Civardi G, Vallisa D, Bertè R, et al. Focal liver lesions in non-Hodgkin's lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection. Eur J Cancer 2002; 38:2382.
  53. Aozasa K, Inoue A, Tajima K, et al. Malignant lymphomas of the thyroid gland. Analysis of 79 patients with emphasis on histologic prognostic factors. Cancer 1986; 58:100.
  54. Gill PS, Chandraratna PA, Meyer PR, Levine AM. Malignant lymphoma: cardiac involvement at initial presentation. J Clin Oncol 1987; 5:216.
  55. Gleeson MJ, Bennett MH, Cawson RA. Lymphomas of salivary glands. Cancer 1986; 58:699.
  56. Harris GJ, Tio FO, Von Hoff DD. Primary adrenal lymphoma. Cancer 1989; 63:799.
  57. Bostwick DG, Mann RB. Malignant lymphomas involving the prostate. A study of 13 cases. Cancer 1985; 56:2932.
  58. Doll DC, Weiss RB. Malignant lymphoma of the testis. Am J Med 1986; 81:515.
  59. Paladugu RR, Bearman RM, Rappaport H. Malignant lymphoma with primary manifestation in the gonad: a clinicopathologic study of 38 patients. Cancer 1980; 45:561.
  60. Woolley PV 3rd, Osborne CK, Levi JA, et al. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer 1976; 38:1026.
  61. Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. J Surg Oncol 2002; 80:19.
  62. Feinstein AJ, Ciarleglio MM, Cong X, et al. Parotid gland lymphoma: prognostic analysis of 2140 patients. Laryngoscope 2013; 123:1199.
  63. Ahmad AK, Hui P, Litkouhi B, et al. Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience. Int J Gynecol Cancer 2014; 24:1250.
  64. Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2:109.
  65. Mead GM, Kennedy P, Smith JL, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases. Q J Med 1986; 60:699.
  66. Perry JR, Deodhare SS, Bilbao JM, et al. The significance of spinal cord compression as the initial manifestation of lymphoma. Neurosurgery 1993; 32:157.
  67. Herman TS, Hammond N, Jones SE, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer 1979; 43:390.
  68. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29:252.
  69. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkin's lymphomas. Cancer 1980; 45:545.
  70. Mohammed WA, Doshi R. Spinal epidural malignant lymphoma presenting with spinal cord compression. Clin Neuropathol 1995; 14:237.
  71. Giglio P, Gilbert MR. Neurological complications of non-Hodgkin's lymphoma. In: Lymphoma of the Nervous System, Batchelor TT (Ed), Butterworth Heinemann, Amsterdam 2004. p.107.
  72. Oviatt DL, Kirshner HS, Stein RS. Successful chemotherapeutic treatment of epidural compression in non-Hodgkin's lymphoma. Cancer 1982; 49:2446.
  73. Ghobrial IM, Buadi F, Spinner RJ, et al. High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer 2004; 100:2403.
  74. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.
  75. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3048.
  76. Slap GB, Connor JL, Wigton RS, Schwartz JS. Validation of a model to identify young patients for lymph node biopsy. JAMA 1986; 255:2768.
  77. Slap GB, Brooks JS, Schwartz JS. When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA 1984; 252:1321.
  78. Pangalis GA, Vassilakopoulos TP, Boussiotis VA, Fessas P. Clinical approach to lymphadenopathy. Semin Oncol 1993; 20:570.
  79. Benign and Malignant Lymphadenopathies: Clinical and Laboratory Diagnosis, Pangalis G, Polliack A (Eds), Harwood Academic Publishers, Chur, Switzerland 1993. p.31.
  80. Pappa VI, Hussain HK, Reznek RH, et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol 1996; 14:2427.
  81. Ben-Yehuda D, Polliack A, Okon E, et al. Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable. J Clin Oncol 1996; 14:2431.
  82. Lachar WA, Shahab I, Saad AJ. Accuracy and cost-effectiveness of core needle biopsy in the evaluation of suspected lymphoma: a study of 101 cases. Arch Pathol Lab Med 2007; 131:1033.
  83. Asoglu O, Porter L, Donohue JH, Cha SS. Laparoscopy for the definitive diagnosis of intra-abdominal lymphoma. Mayo Clin Proc 2005; 80:625.
  84. Lee Y, Terry R, Lukes RJ. Lymph node biopsy for diagnosis: a statistical study. J Surg Oncol 1980; 14:53.
  85. Lee YT, Terry R, Lukes RJ. Biopsy of peripheral lymph nodes. Am Surg 1982; 48:536.
  86. Sriwatanawongsa V, Cardoso R, Chang P. Incidence of malignancy in peripheral lymph node biopsy. Am Surg 1985; 51:587.
  87. Doberneck RC. The diagnostic yield of lymph node biopsy. Arch Surg 1983; 118:1203.
  88. Steinfort DP, Conron M, Tsui A, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for the evaluation of suspected lymphoma. J Thorac Oncol 2010; 5:804.
  89. Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004; 22:3046.
  90. Florentine BD, Staymates B, Rabadi M, et al. The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer 2006; 107:406.
  91. Hunter S, Samir A, Eisner B, et al. Diagnosis of renal lymphoma by percutaneous image guided biopsy: experience with 11 cases. J Urol 2006; 176:1952.
  92. Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.
  93. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.
  94. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110:29.
  95. Siebert JD, Harvey LA, Fishkin PA, et al. Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting. Am J Clin Pathol 2001; 115:650.
  96. Lester JF, Dojcinov SD, Attanoos RL, et al. The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol 2003; 123:463.
  97. Proctor IE, McNamara C, Rodriguez-Justo M, et al. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J Clin Oncol 2011; 29:1431.
  98. Zeppa P, Marino G, Troncone G, et al. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer 2004; 102:55.
  99. Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012; 26:2159.
  100. van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007; 21:201.
  101. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123:1214.
  102. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990; 8:1163.
  103. Foucar K, McKenna RW, Frizzera G, Brunning RD. Bone marrow and blood involvement by lymphoma in relationship to the Lukes--Collins classification. Cancer 1982; 49:888.
  104. Ponzoni M, Li CY. Isolated bone marrow non-Hodgkin's lymphoma: a clinicopathologic study. Mayo Clin Proc 1994; 69:37.
  105. Bennett JM, Cain KC, Glick JH, et al. The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1986; 4:1462.
  106. McKenna RW, Bloomfield CD, Brunning RD. Nodular lymphoma: bone marrow and blood manifestations. Cancer 1975; 36:428.
  107. Stein RS, Ultmann JE, Byrne GE Jr, et al. Bone marrow involvement in non-Hodgkin's lymphoma: implications for staging and therapy. Cancer 1976; 37:629.
  108. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011; 29:1452.